I agree that this site is using cookies. You can find further informations here.
X
Villaruz, L.C.
67  results:
OpenAccess-fulltext X
Search for persons X
?
1

A single-arm, multicenter, phase II trial of osimertinib in..:

Villaruz, L.C ; Wang, X ; Bertino, E.M...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163152/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cel..:

Carbone, D. P ; Reck, M ; Paz-Ares, L...
https://research.rug.nl/en/publications/47eb4225-8235-4eb0-bbaf-d81902ddf2a9.  , 2017
Link: https://hdl.handle.net/1..
 
?
3

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cel..:

Carbone, D.P ; Reck, M ; Paz-Ares, L...
info:eu-repo/semantics/altIdentifier/doi/10.1056/NEJMoa1613493.  , 2017
Link: https://serval.unil.ch/n..
 
?
4

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cel..:

Carbone, D.P ; Reck, M ; Paz-Ares, L...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487310/.  , 2017
Link: http://www.ncbi.nlm.nih...
 
?
5

Combination of Itacitinib or Parsaclisib with Pembrolizumab..:

Munster, Pamela ; Iannotti, Nicholas ; Cho, Daniel C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10729644/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
6

Guidance for clinicians and patients with non-small cell lu..:

Villaruz, Liza C ; Socinski, Mark A ; Weiss, Jared
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107372/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and..:

Gentzler, Ryan D ; Villaruz, Liza C ; Rhee, John C...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628589/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
8

A phase II clinical trial evaluating the safety and efficac..:

Shaverdashvili, Khvaramze ; Reyes, Vincent ; Wang, Hong...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10772260/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
9

Phase II Randomized Study of Ramucirumab and Pembrolizumab ..:

Reckamp, Karen L ; Redman, Mary W ; Dragnev, Konstantin H...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9287284/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
10

Durvalumab, tremelimumab alone or in combination with low-d..:

Schoenfeld, Jonathan D ; Giobbie-Hurder, Anita ; Ranasinghe, Srinika...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813905/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Phase 2 Study of Dabrafenib Plus Trametinib in Patients Wit..:

Planchard, David ; Besse, Benjamin ; Groen, Harry J M...
https://research.rug.nl/en/publications/fe336bfb-7384-4e7b-b515-50ff0e34d941.  , 2022
Link: https://hdl.handle.net/1..
 
?
12

Durvalumab plus tremelimumab alone or in combination with l..:

Schoenfeld, Jonathan D ; Giobbie-Hurder, Anita ; Ranasinghe, Srinika...
qt5nv7g5x0.  , 2022
Link: https://escholarship.org..
 
?
13

Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cel..:

Somasundaram, Ashwin ; Socinski, Mark A ; Villaruz, Liza C
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579493/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
14

Phase IB study of osimertinib in combination with navitocla..:

Bertino, Erin M ; Gentzler, Ryan D ; Clifford, Sarah...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976451/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
15

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 I..:

Hunter, Katerina Ancevski ; Socinski, Mark A ; Villaruz, Liza C
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773410/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
1-15